Bernard Gilly's guest appearances

Bernard Gilly

Finding Genius Podcast

Empowered Patient Podcast

B Smart

Thomas Cowan

Beth Israel

Ali Dianaty

Robin Smith

Jim Joyce

James Mackay

Nick West

Sally Embrey

Robert Cobuzzi

Jim Woody

Hamid Khoja

Cory Kidd

John Poothullil

Pierre Noizat

Monica M. Laronda

OwlTail

How can historically misunderstood retinal  neurodegenerative diseases be researched and treated? New discoveries may lead to continuing advancements in treatment for previously thought to be untreatable ailments. Listen in to learn:  How treatment is targeted at specific cells How functions in the eye can be swapped between parts How the optogenetic process works  Dr. Bernard Gilly, The CEO and Co-Founder of GenSight Biologics discusses his work trying to cure blinding diseases and the development of LUMEVOQ. By studying genetic therapies and root causes of optical degenerative diseases, patients who have been blinded by their condition can seek treatment to regain partial vision. Though it is challenging to continue studying improving patients, the therapeutic techniques continue to be improved, and results remain promising. Though treatments and further research have been delayed, the first patient has received treatment and has regained fundamental visual function. This is promising for the future of macular and retinal degeneration treatments. To learn more, visit gensight-biologics.com.   Episode also available on Apple Podcasts: apple.co/30PvU9C

How can historically misunderstood retinal <a href="https://www.findinggeniuspodcast.com/podcasts/potential-applications-of-extracellular-vesicles-in-diagnosing-and-treating-neurodegenerative-diseases-dr-kenneth-witwer-associate-professor-of-molecular-and-comparative-pathobiol/" rel="nofollow" target="_blank"> neurodegenerative diseases</a> be researched and treated? New discoveries may lead to continuing advancements in treatment for previously thought to be untreatable ailments. Listen in to learn: <ul> <li>How treatment is targeted at specific cells</li> <li>How functions in the eye can be swapped between parts</li> <li>How the optogenetic process works</li> </ul> Dr. Bernard Gilly, The CEO and Co-Founder of GenSight Biologics discusses his work trying to cure blinding diseases and the development of LUMEVOQ. By studying genetic therapies and root causes of optical degenerative diseases, patients who have been blinded by their condition can seek treatment to regain partial vision. Though it is challenging to continue studying improving patients, the therapeutic techniques continue to be improved, and results remain promising. Though treatments and further research have been delayed, the first patient has received treatment and has regained fundamental visual function. This is promising for the future of macular and retinal degeneration treatments. To learn more, visit <a href="https://www.gensight-biologics.com" rel="nofollow" target="_blank">gensight-biologics.com</a>. Episode also available on Apple Podcasts: <a href="https://podcasts.apple.com/us/podcast/id1169016854" rel="nofollow" target="_blank">apple.co/30PvU9C</a>

Neurodegenerative Diseases and Optic Neuropathy Treatments for Blinding Conditions Explained By Dr. Bernard Gilly

Bernard Gilly et Romain de Tellier - Portrait d'entrepreneurs avec Stéphane Soumier et B Smart

B Smart - Bernard Gilly et Romain de Tellier - Portrait d'entrepreneurs avec Stéphane Soumier et B Smart

Bernard Gilly GenSight

Bernard Gilly PhD, CEO and Co-Founder, GenSight Biologics talks about the innovative gene therapy treatments GenSight is developing to fight blinding diseases. Bernard sheds light on treating Leber Hereditary Optic Neuropathy (LHON), a mitochondrial rare disease as well as retinitis pigmentosa (RP). Their goal is to change the lives of patients who are either losing their sight or have lost their sight because of a neurodegenerative condition in their retina. @GenSightBio #blindness #LHON #RP #retinitispigmentosa #augmentedvision GenSight-Biologics.com Download the transcript here.

Bernard Gilly PhD, CEO and Co-Founder, GenSight Biologics talks about the innovative gene therapy treatments GenSight is developing to fight blinding diseases. Bernard sheds light on treating Leber Hereditary Optic Neuropathy (LHON), a mitochondrial rare disease as well as retinitis pigmentosa (RP). Their goal is to change the lives of patients who are either losing their sight or have lost their sight because of a neurodegenerative condition in their retina. @GenSightBio #blindness #LHON #RP #retinitispigmentosa #augmentedvision <a href="http://gensight-biologics.com" rel="noopener nofollow" target="_blank">GenSight-Biologics.com</a> <a href="http://empoweredpatientradio.com/using-gene-therapy-to-fight-blindness-with-bernard-gilly-gensight-biologics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here.</a>

Using Gene Therapy to Fight Blindness with Bernard Gilly GenSight Biologics